Brendan Weiss
Brendan Weiss
Abramson Cancer Center, University of Pennsylvania
Potvrđena adresa e-pošte na - Početna stranica
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ...
The lancet oncology 15 (12), e538-e548, 2014
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
S Lonial, BM Weiss, SZ Usmani, S Singhal, A Chari, NJ Bahlis, A Belch, ...
The Lancet 387 (10027), 1551-1560, 2016
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
AP Rapoport, EA Stadtmauer, GK Binder-Scholl, O Goloubeva, DT Vogl, ...
Nature medicine 21 (8), 914-921, 2015
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
J Krejcik, T Casneuf, IS Nijhof, B Verbist, J Bald, T Plesner, K Syed, K Liu, ...
Blood, The Journal of the American Society of Hematology 128 (3), 384-394, 2016
A monoclonal gammopathy precedes multiple myeloma in most patients
BM Weiss, J Abadie, P Verma, RS Howard, WM Kuehl
Blood, The Journal of the American Society of Hematology 113 (22), 5418-5422, 2009
Chimeric antigen receptor T cells against CD19 for multiple myeloma
AL Garfall, MV Maus, WT Hwang, SF Lacey, YD Mahnke, JJ Melenhorst, ...
New England Journal of Medicine 373 (11), 1040-1047, 2015
B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
AD Cohen, AL Garfall, EA Stadtmauer, JJ Melenhorst, SF Lacey, ...
The Journal of clinical investigation 129 (6), 2210-2221, 2019
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
A Chari, A Suvannasankha, JW Fay, B Arnulf, JL Kaufman, ...
Blood, The Journal of the American Society of Hematology 130 (8), 974-981, 2017
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
SZ Usmani, BM Weiss, T Plesner, NJ Bahlis, A Belch, S Lonial, ...
Blood, The Journal of the American Society of Hematology 128 (1), 37-44, 2016
Racial disparities in incidence and outcome in multiple myeloma: a population-based study
AJ Waxman, PJ Mink, SS Devesa, WF Anderson, BM Weiss, ...
Blood, The Journal of the American Society of Hematology 116 (25), 5501-5506, 2010
International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment
MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ...
Journal of Clinical Oncology 34 (13), 1544-1557, 2016
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
N Leung, F Bridoux, V Batuman, A Chaidos, P Cockwell, VD D’Agati, ...
Nature Reviews Nephrology 15 (1), 45-59, 2019
How I treat monoclonal gammopathy of renal significance (MGRS)
JP Fermand, F Bridoux, RA Kyle, E Kastritis, BM Weiss, MA Cook, ...
Blood, The Journal of the American Society of Hematology 122 (22), 3583-3590, 2013
Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis
O Landgren, BM Weiss
Leukemia 23 (10), 1691-1697, 2009
Daratumumab-based treatment for immunoglobulin light-chain amyloidosis
E Kastritis, G Palladini, MC Minnema, AD Wechalekar, A Jaccard, HC Lee, ...
New England Journal of Medicine 385 (1), 46-58, 2021
Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis
AJ Waxman, S Clasen, WT Hwang, A Garfall, DT Vogl, J Carver, ...
JAMA oncology 4 (3), e174519-e174519, 2018
First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction
MA Gertz, H Landau, RL Comenzo, D Seldin, B Weiss, J Zonder, G Merlini, ...
Journal of Clinical Oncology 34 (10), 1097, 2016
Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research Study
A D'Souza, A Dispenzieri, B Wirk, MJ Zhang, J Huang, MA Gertz, RA Kyle, ...
Journal of Clinical Oncology 33 (32), 3741, 2015
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA
G Palladini, E Kastritis, MS Maurer, J Zonder, MC Minnema, ...
Blood, The Journal of the American Society of Hematology 136 (1), 71-80, 2020
Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study
SF Huntington, BM Weiss, DT Vogl, AD Cohen, AL Garfall, PA Mangan, ...
The Lancet Haematology 2 (10), e408-e416, 2015
Sustav trenutno ne može provesti ovu radnju. Pokušajte ponovo kasnije.
Članci 1–20